for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ボストン・サイエント・コーポレーション

BSX

現在値

43.64USD

変化

-0.73(-1.65%)

出来高

7,566,182

本日のレンジ

43.24

 - 

44.08

52週レンジ

32.99

 - 

46.28

∙ 約20分前の相場を表示しています。

適時開示

FDA Says Boston Scientific Recalls Ingenio Family Of Pacemakers And Crt-Ps Due To Risk Of Transition To Safety Mode

Aug 10 (Reuters) - FDA::FDA SAYS BOSTON SCIENTIFIC RECALLS INGENIO FAMILY OF PACEMAKERS AND CRT-PS DUE TO RISK OF TRANSITION TO SAFETY MODE.FDA SAYS BOSTON SCIENTIFIC'S RECALL OF INGENIO FAMILY OF PACEMAKERS AND CRT-PS IDENTIFIED AS A CLASS I RECALL.FDA SAYS THERE HAVE BEEN 65 REPORTED INCIDENTS, INCLUDING THREE INJURIES WHICH REQUIRED PATIENTS TO RECEIVE TEMPORARY EXTERNAL PACING.Further company coverage: BSX.N. ((Reuters.Briefs@thomsonreuters.com;)).

FDA Says Boston Scientific Recalling Ingenio Family Of Pacemakers And CRT-Ps

Aug 6 (Reuters) - U.S. FDA: :FDA - BOSTON SCIENTIFIC IS RECALLING INGENIO FAMILY OF PACEMAKERS AND CRT-PS DUE TO THE RISK OF INCORRECT TRANSITION TO SAFETY MODE.FDA - HAS IDENTIFIED RECALL OF INGENIO FAMILY OF PACEMAKERS AND CRT-PS AS A CLASS I RECALL.FDA - THERE HAVE BEEN 65 REPORTED INCIDENTS, INCLUDING 3 INJURIES WHICH REQUIRED PATIENTS TO RECEIVE TEMPORARY EXTERNAL PACING.Further company coverage: BSX.N. ((Reuters.Briefs@thomsonreuters.com;)).

Boston Scientific Reports Q2 Earnings Per Share $0.12

July 27 (Reuters) - Boston Scientific Corp <BSX.N>::SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 19% TO 20% ON ORGANIC BASIS (ADDS SOURCE).BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2021.Q2 GAAP EARNINGS PER SHARE $0.12.Q2 SALES $3.077 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.94 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.37 -- REFINITIV IBES DATA.Q2 ADJUSTED EARNINGS PER SHARE $0.40.QTRLY CARDIOVASCULAR SEGMENT SALES $1,263 MILLION VERSUS $834 MILLION REPORTED LAST YEAR.SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 21%-22% ON A REPORTED BASIS.BOSTON SCIENTIFIC-SEES Q3 EPS ON A GAAP BASIS IN A RANGE OF $0.20 TO $0.22 AND ADJUSTED EPS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $0.39 TO $0.41.BOSTON SCIENTIFIC - CO SEES NET SALES GROWTH FOR FY 2021 TO BE IN RANGE OF 21-22 PERCENT ON A REPORTED BASIS & 19 - 20 PERCENT ON AN ORGANIC BASIS.SEES NET SALES GROWTH FOR Q3 TO BE ABOUT 12% TO 14% ON BOTH A REPORTED AND ORGANIC BASIS.SEES 2021 ESTIMATES EPS ON A GAAP BASIS OF $0.79-$0.83, ADJUSTED EPS EXCLUDING CERTAIN CHARGES (CREDITS) OF $1.58-$1.62.FY2021 EARNINGS PER SHARE VIEW $1.58, REVENUE VIEW $11.75 BILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.40, REVENUE VIEW $2.97 BILLION -- REFINITIV IBES DATA.Further company coverage: <BSX.N>. ((Reuters.Briefs@thomsonreuters.com;)).

Boston Scientific Exercises Option To Acquire Farapulse Inc

June 24 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC CORP - EXERCISED ITS OPTION TO ACQUIRE REMAINING SHARES OF FARAPULSE INC.BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF AN UPFRONT PAYMENT OF APPROXIMATELY $295 MILLION FOR 73 PERCENT STAKE NOT YET OWNED.BOSTON SCIENTIFIC CORP - ON AN ADJUSTED BASIS, TRANSACTION IS EXPECTED TO BE SLIGHTLY DILUTIVE TO ADJUSTED EPS IN 2021 AND 2022.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE MORE DILUTIVE DILUTIVE TO ADJUSTED EARNINGS PER SHARE (EPS) IN 2021 AND 2022.

FDA Says Boston Scientific Recalls VICI VENOUS STENT System And VICI RDS VENOUS STENT System

May 21 (Reuters) - U.S FDA: :FDA - BOSTON SCIENTIFIC CORPORATION RECALLS VICI VENOUS STENT SYSTEM AND VICI RDS VENOUS STENT SYSTEM FOR POTENTIAL OF STENT MIGRATION.FDA - IDENTIFIED RECALL OF BOSTON SCIENTIFIC'S VICI VENOUS STENT SYSTEM AND VICI RDS VENOUS STENT SYSTEM AS A CLASS I RECALL.

Boston Scientific Corp Says On May 10, Entered Into $2.750 Billion Revolving Credit Agreement

May 13 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC CORP - ON MAY 10, ENTERED INTO $2.750 BILLION REVOLVING CREDIT AGREEMENT.BOSTON SCIENTIFIC CORP - 2021 REVOLVING CREDIT AGREEMENT MATURES ON MAY 10, 2026, WITH ONE-YEAR EXTENSION OPTIONS SUBJECT TO CERTAIN CONDITIONS.

Boston Scientific Announces Results For First Quarter 2021

April 28 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2021.Q1 GAAP EARNINGS PER SHARE $0.23.Q1 SALES $2.752 BILLION.Q1 ADJUSTED EARNINGS PER SHARE $0.37.NOW SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 16%-19% ON A REPORTED BASIS, AND ABOUT 15%-18% ON AN ORGANIC BASIS.NOW ESTIMATES 2021 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.81 TO $0.88 PER SHARE.ESTIMATES 2021 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $1.53 TO $1.60 PER SHARE.QTRLY CARDIOVASCULAR SEGMENTS SALES $1,129 MILLION VERSUS $1,026 MILLION.FY2021 EARNINGS PER SHARE VIEW $1.54, REVENUE VIEW $11.43 BILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.31, REVENUE VIEW $2.62 BILLION -- REFINITIV IBES DATA.CO ESTIMATES NET SALES GROWTH FOR Q2 OF 2021, TO BE IN A RANGE OF ABOUT 46 TO 50 PERCENT ON A REPORTED BASIS.NOW ESTIMATES Q2 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.16 TO $0.18 PER SHARE.NOW ESTIMATES Q2 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $0.36 TO $0.38 PER SHARE.Q2 EARNINGS PER SHARE VIEW $0.35 -- REFINITIV IBES DATA.

Boston Scientific Receives FDA Approval For Therasphere Y-90 Glass Microspheres

March 18 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC RECEIVES FDA APPROVAL FOR THERASPHERE™ Y-90 GLASS MICROSPHERES.

Boston Scientific Announces Agreement To Acquire Lumenis Ltd Surgical Business From Baring Private Equity Asia

March 3 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE LUMENIS LTD. SURGICAL BUSINESS FROM BARING PRIVATE EQUITY ASIA.BOSTON SCIENTIFIC CORP - DEAL FOR AN UPFRONT CASH PAYMENT OF $1.07 BILLION.BOSTON SCIENTIFIC CORP - BPEA WILL RETAIN OWNERSHIP OF LUMENIS GLOBAL AESTHETICS AND OPHTHALMOLOGY BUSINESSES..BOSTON SCIENTIFIC CORP - IMPACT TO ADJUSTED EARNINGS PER SHARE IS EXPECTED TO BE IMMATERIAL IN 2021.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE DILUTIVE IN 2021 AND LESS DILUTIVE OR INCREASINGLY ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - SEES DEAL ABOUT TWO CENTS ACCRETIVE IN 2022 AND INCREASINGLY ACCRETIVE THEREAFTER.BOSTON SCIENTIFIC CORP - LUMENIS' 2021 NET SALES ANTICIPATED TO BE APPROXIMATELY $200 MILLION.

Temasek Holdings (Private) Ltd Reports Stake In Airbnb, DoorDash; Ups Stake in Uber, Datadog

Feb 16 (Reuters) - TEMASEK HOLDINGS (PRIVATE): :TEMASEK HOLDINGS (PRIVATE) LTD REPORTS STAKE OF 100,000 CLASS A SHARES IN AIRBNB INC - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD UPS STAKE IN AMAZON.COM BY 53.1% TO 90,146 SHARES.TEMASEK HOLDINGS (PRIVATE) LTD REPORTS STAKE OF 6.1 MILLION CLASS A SHARES IN DOORDASH.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN TENCENT MUSIC BY 99% TO 11,313 SPONSORED ADSS.TEMASEK HOLDINGS (PRIVATE) LTD UPS STAKE IN UBER TECHNOLOGIES INC FROM 10,988 SHARES TO 33,455 SHARES.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 232,545 SHARES IN BOSTON SCIENTIFIC.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 112,082 SHARES IN SALESFORCE.COM INC.TEMASEK HOLDINGS (PRIVATE) LTD UPS SHARE STAKE IN DATADOG INC BY 52.7% TO 93,373 CLASS A SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2020 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2020.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up